top of page
Cancer Drug Fund Delistings
Cancer52 comment on Cancer Drug Fund announcement of 4 September 2015.
Cancer52 Policy Briefing identifies calls for rare and less common cancers
The Achieving World-Class Cancer Outcomes: A Strategy for England 2015-2020 was published in July 2015. Cancer52, a coalition of more...
“Rare and Less Common Cancers: Incidence and Mortality in England, 2010 to 2013”
We are delighted to announce that our new report “Rare and Less Common Cancers: Incidence and Mortality in England, 2010 to 2013” is...
Parliamentary Questions and Answers
Following our successful Parliamentary event in December, details of how the last government answered our questions on rare and less...
Consultation on Investing in Specialised Services
On 23 April, Cancer52 responded to the NHS public consultation on Investing in Specialised Services. Read more of our submission.
Jonathan Pearce appointed as Chair of Cancer52
Cancer52 is delighted to announce that Jonathan Pearce, chief executive of the Lymphoma Association, has been appointed as Chair of...
Cancer52 Chair joins NHS England Cancer Taskforce
www.england.nhs.uk/2015/01/11/beat-cancer On Sunday 11th January 2015 NHS England announced details of a new independent taskforce being...
Cancer52 Statement re Cancer Drug Fund (CDF) Delistings
As a member of the Cancer Drug Fund (CDF) Charity Group Cancer52 has signed an open letter to Professor Peter Clark, Chair of the CDF....
Parliamentary event "The hidden majority - improving outcomes for people with rare and less com
We are delighted to be hosting a parliamentary event in December 2014, hosted by John Baron MP, Chair of the All-Party Parliamentary...
Cancer Drugs Fund Consultation
On 31st October 2014 Cancer52 submitted its response to the NHS England Consultation: Proposals for a sustainable Cancer Drugs Fund. You...
bottom of page